Status:

COMPLETED

Biomarker Discovery in Patients With Advanced Biliary Tract Cancer

Lead Sponsor:

CHA University

Collaborating Sponsors:

Dong-A Pharmaceutical

Conditions:

Biliary Tract Cancer

Cholangiocarcinoma

Eligibility:

All Genders

19+ years

Brief Summary

Biliary tract cancer is a rare gastrointestinal malignant neoplasm and includes intrahepatic cholangiocarcinoma, extrahepatic cholangiocarcinoma, and gall bladder cancer. Curative surgical resection o...

Detailed Description

Using biopsy specimen (formalin fixed paraffin embedded tissue), in-house NGS and RNA-sequencing will be performed simultaneously. Through this, investigators will discover biomarkers based on multi-o...

Eligibility Criteria

Inclusion

  • Age ≥ 19 years old
  • Capable of understanding and complying with the protocol requirements and signed informed consent
  • The patients were confirmed as bilary tract cancer (gall bladder cancer, extrahepatic cholangiocarcinoma, intrahepatic cholangiocarcinoma) by histopathology or cytology
  • Patients with inoperable or metastatic or recurrent biliary tract cancer
  • Patients who underwent in-house next-generation sequencing
  • Patients planning to receive Gemcitabine, Cisplatin, nab-paclitaxel triplet chemotherapy
  • At least one measurable objective lesion was identified based on the RECIST 1.1 criteria
  • Eastern Cooperative Oncology Group (ECOG) performance status of 0-1.
  • The expected survival a ≥3 months

Exclusion

  • The subject has uncontrolled, significant intercurrent or recent illness including infection for organ failure
  • Prior palliative chemotherapy for biliary tract cancer
  • Dementia, altered mental state, or any mental illness that prevents understanding or informed consent
  • Other conditions that researchers not think to be suitable for enrollment.

Key Trial Info

Start Date :

April 14 2021

Trial Type :

OBSERVATIONAL

Allocation :

ACTUAL

End Date :

December 31 2023

Estimated Enrollment :

119 Patients enrolled

Trial Details

Trial ID

NCT04871321

Start Date

April 14 2021

End Date

December 31 2023

Last Update

August 26 2025

Active Locations (1)

Enter a location and click search to find clinical trials sorted by distance.

Page 1 of 1 (1 locations)

1

CHA Bundang Medical Center

Seongnam-si, Gyeonggi-do, South Korea, 13496